AbbVie Highlights Lung Cancer Pipeline Data at WCLC 2026

North Chicago, Illinois, USA, August 21, 2026

ABBV-1480 Shows Activity in Advanced NSCLC

One of the major presentations at WCLC 2026 will feature Phase 1b data for ABBV-1480, developed by AbbVie in partnership with RemeGen. The investigational therapy is a PD-1/VEGF bispecific antibody designed to simultaneously target two pathways involved in tumor biology and immune regulation. The study is evaluating ABBV-1480 in combination with platinum-based chemotherapy as a potential first-line treatment for advanced NSCLC, including both squamous and non-squamous disease. According to the company, the 10 mg/kg dose has been identified as the recommended Phase 3 dose for further development in combination regimens. At this dose, the reported objective response rate was 90.0% in squamous NSCLC and 75.9% in non-squamous NSCLC. These findings will be presented through an oral WCLC presentation and provide clinical data supporting continued investigation of the program.The company is also advancing a Phase 3 randomized, double-blind trial of RC148 with chemotherapy in first-line squamous NSCLC. The continued development reflects growing interest in combination immunotherapy approaches designed to address multiple biological mechanisms within lung tumors. However, the reported response rates are from an early-stage clinical study, and additional randomized Phase 3 evidence will be required to determine the potential clinical benefit and establish the therapy’s future role in treatment.

Targeted ADC Programs Expand Lung Cancer Strategy

AbbVie’s WCLC program also includes new research involving telisotuzumab adizutecan (Temab-A), a targeted antibody-drug conjugate directed toward c-Met, as well as the investigational ABBV-706 program. Presentations will examine Temab-A in combination with a PD-1 inhibitor in untreated advanced non-squamous NSCLC, while additional research will explore clinical characteristics and patient-reported outcomes associated with peripheral neuropathy in patients receiving telisotuzumab-based treatment. These studies are intended to provide further insight into treatment activity, safety and patient experience in advanced lung cancer. The WCLC program also includes research into ABBV-706, an investigational ADC being studied in small cell lung cancer and other advanced solid tumors. Presentations will address the safety profile of ABBV-706, including hematologic and gastrointestinal toxicity, as well as pneumonitis and interstitial lung disease in the first-in-human study. Additional research examining SEZ6 expression across major clinical and demographic groups of SCLC patients could contribute to the identification of biomarkers and patient populations that may benefit from targeted therapeutic strategies.

AbbVie Builds Broad Oncology Pipeline

The collection of WCLC 2026 presentations illustrates AbbVie’s strategy of combining next-generation immunotherapies, targeted ADCs and potential combination treatments to address different aspects of lung cancer biology. The company is pursuing programs across both NSCLC and SCLC while generating clinical and translational evidence that may help guide future development and patient selection. The research also emphasizes the importance of biomarkers and real-world evidence in developing more tailored approaches to lung cancer treatment.The WCLC data represent an important research update for AbbVie’s oncology pipeline, but several of the therapies discussed remain investigational and have not been established as approved treatments for the indications described. Future clinical trials will be important in determining whether the observed findings translate into meaningful improvements in outcomes for people living with lung cancer. AbbVie’s continued investment across bispecific antibodies, antibody-drug conjugates and biomarker-driven oncology research highlights the broader industry focus on developing increasingly targeted treatment strategies for difficult-to-treat cancers.

Source: AbbVie press relese